10-Q: InnovAge Reports Strong Q1 Earnings, Revenue Jumps 15%

InnovAge Holding Corp. announced a significant turnaround in its first fiscal quarter, reporting positive net income and robust revenue growth driven by increased capitation rates and participant enrollment.

Summary

• InnovAge Holding Corp. reported total revenues of $236.1 million for the three months ended September 30, 2025, a 15.1% increase from $205.1 million in the prior year period.
• Capitation revenue grew by 15.1% to $235.8 million, primarily due to a 4.7% increase in capitation rates and a 9.9% increase in member months.
• Net income attributable to InnovAge Holding Corp. was $8.0 million, a substantial improvement from a net loss of $4.9 million in the same period last year.
• Basic and diluted earnings per share (EPS) turned positive at $0.06, compared to a loss of $0.04 per share in the prior year.
• Adjusted EBITDA increased by 172.4% to $17.6 million, with Adjusted EBITDA Margin rising to 7.5% from 3.2%.
• Center-level Contribution Margin increased by 48.7% to $51.4 million, representing 21.8% of revenue, up from 16.8%.
• The company served approximately 7,890 PACE participants as of September 30, 2025, operating 20 centers across six states.
• External provider costs increased by a modest 1.5% to $108.9 million, despite a 9.9% increase in member months, due to a 7.6% decrease in cost per participant.
• The decrease in cost per participant was attributed to lower permanent nursing facility and short-stay skilled nursing facility utilization, and reduced pharmacy expense due to higher rebates and the transition to in-house pharmacy services.
• Cash and cash equivalents increased by $3.0 million to $67.1 million as of September 30, 2025.
• The company completed an Amendment No. 2 to its Credit Agreement on August 8, 2025, refinancing its Term Loan Facility to $50.7 million and extending the maturity date of both the Term Loan A Facility and Revolving Credit Facility to August 8, 2028.
• InnovAge entered into a joint venture agreement with Tampa General Hospital on August 15, 2025, to develop a PACE center in Tampa, Florida, contributing $28.8 million for a 90% interest.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial performance with significant revenue growth, a return to profitability, and improved EBITDA margins. However, ongoing legal proceedings, regulatory challenges, and delays in de novo center expansion introduce notable uncertainties and risks that temper overall sentiment.

Positives

• Net income attributable to InnovAge Holding Corp. significantly improved to $8.0 million from a net loss of $4.9 million year-over-year.
• Basic and diluted EPS turned positive at $0.06, indicating a return to profitability.
• Total revenues increased by 15.1% to $236.1 million, driven by strong capitation revenue growth.
• Capitation rates increased by 4.7%, including a 7.9% annual increase in Medicaid rates and a 3.7% increase in Medicare rates.
• Member months grew by 9.9%, reflecting successful participant enrollment growth in California, Florida, and Colorado centers.
• Adjusted EBITDA surged by 172.4% to $17.6 million, demonstrating improved operational efficiency.
• Adjusted EBITDA Margin expanded to 7.5% from 3.2%, indicating better profitability per dollar of revenue.
• Center-level Contribution Margin increased by 48.7% to $51.4 million, with its percentage of revenue rising to 21.8% from 16.8%.
• Cost per participant for external provider costs decreased by 7.6%, attributed to lower nursing facility utilization and improved pharmacy expense management.
• Cash and cash equivalents increased by $3.0 million, strengthening liquidity.
• Successful refinancing of the Term Loan Facility and extension of debt maturity to August 2028 provides financial stability.
• The joint venture with Tampa General Hospital for a new PACE center in Florida expands the company's market presence and growth opportunities.

Negatives

• Cost of care (excluding depreciation and amortization) increased by 19.7% to $75.9 million, primarily due to a $4.5 million increase in salaries, wages, and benefits from increased headcount and higher wage rates.
• Third-party fees and shipping costs associated with in-house pharmacy services contributed $4.9 million to the increase in cost of care.
• Fleet costs, including contract transportation, increased by $2.1 million, adding to the cost of care.
• Sales and marketing expenses rose by 17.1% to $7.6 million due to increased headcount, wage rates, and marketing spend.
• Corporate, general and administrative expenses increased by 9.9% to $30.3 million, driven by higher employee compensation, software license fees, and professional services.
• The company recorded an additional loss on assets held for sale of $0.1 million from the divestiture of its senior housing interest.
• Ongoing civil investigative demands from the Colorado Attorney General and the Department of Justice pose significant legal and financial uncertainty, with possible losses currently unestimable.
• A stockholder class action lawsuit resulted in a $27.0 million settlement agreement, with InnovAge's share being $10.1 million after insurer payments, pending final court approval.
• A derivative lawsuit by a purported stockholder alleging breach of fiduciary duty against current and former officers and directors is ongoing, with potential for resolution discussions.
• An arbitration demand from Grane Supply, Inc. (former pharmacy services vendor) for breach of contract and confidentiality is ongoing, with a final merits hearing expected in early 2026, and possible losses unestimable.
• The California Department of Health Care Services (DHCS) has suspended attestations for planned de novo centers in Downey and Bakersfield, California, precluding their opening until deficiencies are remediated.

Risks

• Viability of growth strategy, including ability to find suitable geographies for new centers and obtain licenses (e.g., Downey and Bakersfield, CA), and ramp up de novo centers (e.g., Florida).
• Ability to identify, successfully complete, and integrate acquisitions, joint ventures, and strategic partnerships.
• Ability to attract new participants and retain existing participants to implement growth strategy.
• Impact of ongoing macroeconomic challenges, including labor shortages, labor competition, inflation, tariffs, trade disputes, and effects of a prolonged government shutdown.
• Results of periodic inspections, reviews, audits, and investigations under federal and state government programs, and ability to cure identified deficiencies.
• Adverse impact of legal proceedings, enforcement actions, and litigation, including current civil investigative demands from federal and state agencies and stockholder lawsuits.
• Risk that the cost of providing services will exceed compensation under the PACE program.
• Increased costs and expenditures and inability to execute or realize benefits of clinical and operational value initiatives.
• Dependence of revenues and operations upon a limited number of government payors, including risk of sudden loss of government contracts.
• Risk that submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants.
• Impact of state and federal efforts to reduce healthcare spending, including the One Big Beautiful Bill Act (OBBBA) mandates for Medicaid spending reductions, new work requirements, and cost-sharing measures.
• Concentration of a significant percentage of operations in the State of Colorado.
• Ability to compete in the healthcare industry.
• Difficulty to predict future operating results, which could cause results to fall below guidance, targets, or goals.
• Dependence on senior management team and other key employees.
• Impact of failures by suppliers to meet needs, or limitations on ability to effectively access new technology or medical products.
• Ability to manage operations effectively, execute business plan, maintain effective levels of service and participant satisfaction, and adequately address competitive challenges.
• Impact on business of security breaches, loss of data, or other disruptions, causing compromise of sensitive information or preventing access to critical information.
• Ability to accurately estimate incurred but not reported medical expense or risk scores of participants.
• Impact on business of termination of leases, increases in rent, or inability to renew or extend leases.
• Ability to adhere to complex and changing government laws and regulations in the healthcare industry, including U.S. Healthcare reform, corporate practice of medicine, and HIPAA.
• Status as a controlled company and volatility of stock price.
• Ability to comply with continued listing requirements of Nasdaq.

Future Outlook

InnovAge anticipates increased cost of care from third-party service providers due to budget pressures from the OBBBA and state Medicaid program cuts, as well as possible increases in medical supply costs. The company believes its clinical and operational value initiatives may offset these anticipated increases. Labor market pressures, particularly in geriatrics and direct care, are expected to continue increasing wage and benefit costs, potentially impacting enrollment capacity. Delays in Medicaid enrollment and redetermination, though lessened, could persist or worsen due to the OBBBA. The company plans to continue investing in its centers, value-based care model, and sales and marketing to support long-term growth, expecting short-term expense increases but long-term positive impacts. The company intends to retain substantially all available funds and future earnings to fund business development and repay indebtedness, not anticipating cash dividends in the foreseeable future.

Management Comments

• We believe that our clinical value initiatives and operational value initiatives, which continue to be developed, may assist us in offsetting the increased cost of care anticipated for fiscal year 2026.
• To mitigate labor market challenges, we implemented targeted compensation and retention initiatives, along with operational measures to help improve productivity and reduce reliance on agency staffing.
• We continue to strengthen our encounter data submission process so that our revenue more accurately reflects the acuity of the populations we serve.
• We plan to invest in future growth judiciously and maintain focus on managing our results of operations.
• In the short term, we expect these activities to increase our expenses as a percentage of revenue, but in the longer term, we anticipate that these investments will positively impact our business and results of operations.

Industry Context

The healthcare sector, particularly geriatrics and direct care, continues to face significant workforce shortages and intense competition for staff, leading to increased wage and benefit costs. Government policies like the OBBBA are mandating reductions in federal Medicaid spending, which could lead to state budgetary pressures, potential rate reductions, and administrative delays for PACE providers. Macroeconomic trends, including tariffs and trade disputes, could also lead to higher medical supply prices and supply chain disruptions. Despite these headwinds, the demand for all-inclusive care for the frail elderly population remains strong, and InnovAge, as the largest PACE provider, is positioned to benefit from this demographic trend, provided it can effectively manage costs and navigate regulatory complexities.

Comparison to Industry Standards

• InnovAge manages participants with an average risk adjustment factor (RAF) score of 2.43, which is higher than other Medicare-eligible patients, including those in Medicare Advantage (MA) programs, indicating a more complex and medically fragile population.
• The company's average participant tenure of 3.2 years and low voluntary disenrollment rate of 7.0% annually over the last three fiscal years suggest strong participant satisfaction and retention, which is a positive indicator compared to typical healthcare provider churn rates.

Management Changes

Corporate Governance

Legal Proceedings

• Civil investigative demand from the Attorney General for the State of Colorado (July 2021) regarding Medicaid billing, patient services, and referrals in Colorado PACE program. Unable to estimate possible losses.
• Civil investigative demand from the Department of Justice (DOJ) (February 2022, supplemental in December 2022) under the Federal False Claims Act regarding audits, billing, orders tracking, and quality/timeliness of patient services in PACE programs across California, Colorado, New Mexico, Pennsylvania, and Virginia. Unable to estimate possible losses.
• Civil investigative demand from the DOJ (October 2024) under the Federal False Claims Act regarding the company's relationship with residential care facilities, related housing costs, and enrollment practices in California, Colorado, Virginia, and New Mexico. Unable to estimate possible losses.
• Putative class action complaint (Securities Action) filed October 14, 2021, alleging violations of Securities Act of 1933 and Securities Exchange Act of 1934. Settlement agreement for $27.0 million (company's share $10.1 million) received preliminary approval on June 17, 2025, with final approval hearing rescheduled to December 5, 2025.
• Derivative claims lawsuit filed May 15, 2023, by a purported stockholder against current and former officers and directors for breach of fiduciary duty related to CMS sanctions and alleged misstatements. Litigation is stayed, and parties are discussing a potential resolution. Unable to estimate possible losses.
• Arbitration demand from Grane Supply, Inc. (former pharmacy services vendor) filed June 17, 2025, asserting claims for breach of contract and confidentiality. A final merits hearing is expected in early 2026. Unable to estimate possible losses.

Related Party Transactions

• InnovAge Florida PACE Orlando: Joint venture with Orlando Health (OHI), where InnovAge contributed $26.1 million for a 90% controlling interest and OHI contributed $2.9 million for a 10% interest.
• InnovAge Florida PACE Tampa: Joint venture with Tampa General Hospital, where InnovAge contributed $28.8 million for a 90% controlling interest and Tampa General Hospital contributed $3.2 million for a 10% interest.
• InnovAge Sacramento: Joint venture with Adventist Health System/West and Eskaton Properties, Incorporated, where InnovAge holds a 59.9% membership interest and noncontrolling interest holders have a put right to require repurchase of their interests at fair value after 2028.

Stakeholder Impact

• Shareholders: Positive net income and EPS, strong revenue growth, and improved EBITDA could lead to increased shareholder value. However, ongoing legal and regulatory risks, including potential unestimable losses from civil investigative demands and arbitration, introduce uncertainty.
• Employees: Increased headcount and higher wage rates contributed to higher cost of care, indicating investment in the workforce. However, labor market shortages and competition for healthcare professionals remain a challenge.
• Participants: The company's focus on high-acuity, dual-eligible seniors and its comprehensive care model aim to improve quality of care. Delays in Medicaid redetermination and potential impacts of the OBBBA could affect participant enrollment and access to services.
• Government Payors (Medicare/Medicaid): The company's revenues are highly dependent on capitated payments from these payors. Changes in government policies, such as the OBBBA's Medicaid spending reductions, could impact funding and rates.
• Suppliers/Vendors: Transition to in-house pharmacy services has impacted external provider costs and led to arbitration with a former vendor. Macroeconomic trends like tariffs could affect supply chain costs.
• Creditors: Refinancing of the Term Loan Facility and extension of maturity dates provide greater financial stability and predictability for debt obligations.

Next Steps

• The final approval hearing for the $27.0 million Securities Action settlement is rescheduled to December 5, 2025.
• A final merits hearing in the arbitration with Grane Supply, Inc. is expected to occur in early 2026.
• Parties in the derivative lawsuit are discussing a potential resolution, with an update requested by November 10, 2025.
• The company plans to adopt ASU 2023-09 (Income Taxes) prospectively in the first quarter of fiscal 2027.
• The company is evaluating the effects of ASU 2024-03 (Expense Disaggregation Disclosures) and plans to adopt it for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027.
• InnovAge will continue to cooperate with the Colorado Attorney General and the Department of Justice regarding ongoing civil investigative demands.
• The company needs to remediate deficiencies at its Sacramento and San Bernardino centers to potentially restore State Attestations for planned California de novo centers.

Key Dates

Recommendation

InnovAge's Q1 fiscal 2026 results demonstrate a strong financial turnaround, with significant revenue growth, positive net income, and improved EBITDA margins. The company's core business, serving high-acuity PACE participants, shows healthy growth in member months and capitation rates. However, these positives are significantly offset by a complex and uncertain legal and regulatory environment, including multiple civil investigative demands from federal and state agencies, ongoing stockholder litigation, and an arbitration with a former vendor, all with unestimable potential losses. Additionally, delays in de novo center expansion in California and broader industry challenges like labor shortages and the impact of the OBBBA introduce considerable operational and financial risks. Given the strong operational performance but substantial unresolved legal and regulatory overhangs, a 'hold' recommendation is appropriate. Investors should monitor the outcomes of the legal proceedings and the company's ability to navigate regulatory changes and expand its footprint.

Keywords

InnovAge Holding Corp, INNV, PACE, Program of All-Inclusive Care for the Elderly, Healthcare, Managed Care, Elderly Care, Medicare, Medicaid, Capitation Revenue, Financial Results, Q1 2026, Earnings, Adjusted EBITDA, Participant Enrollment, Legal Proceedings, SEC Filing, 10-Q, Healthcare Services, Risk Adjustment Factor, Joint Venture, Corporate Governance